Navigation Links
Adhesion Prevention New Major Market Opportunity, Haemacure Confirms Effectiveness of its Fibrin Sealant in Second Preclinical Study in Adhesion Prevention in a Bleeding Model
Date:9/11/2008

HAE:TSX

MONTREAL, Sept. 11 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, disclosed today the positive results of a second preclinical study conducted on the use of its proprietary lead product candidate, the human fibrin sealant Hemaseel(R)HMN, in preventing the formation of post-surgical adhesions in a bleeding surgical model.

The study compared Haemacure's fibrin sealant to untreated controls, and to two major FDA-approved adhesion prevention products: Interceed(TM) Absorbable Adhesion Barrier (Ethicon) and Seprafilm(R) Adhesion Barrier (Genzyme). Use of Haemacure's fibrin sealant in the presence of blood resulted in a statistically significant reduction in the incidence, extent and severity of adhesions, as compared to the untreated control group. Haemacure's fibrin sealant also was statistically significantly more effective than both Interceed and Seprafilm. For example, the extent of adhesions in both the untreated and Seprafilm groups was three times (54.2%) that in the Haemacure's fibrin sealant group (18%). It was even higher, four times, in the Interceed group (71.7%). Liquid fibrin sealants, such as Haemacure's, are much easier to apply to treatment sites than adhesion barriers such as Interceed. They also lend themselves to laparoscopic application much better than these types of barriers.

This second study, conducted in July 2008, confirms and extends previous pre-clinical results demonstrating the effectiveness of Haemacure's fibrin sealant in adhesion prevention, using its current haemostasis formulation. The previous study, conducted in April 2008, also demonstrated that the use of Haemacure's fibrin sealant resulted in a statistically significant reduction in the incidence, extent and severity of adhesions, as compared to untreated controls. Both studies were designed to evaluate the efficacy of Haemacure's fibrin sealant in a rabbit uterine horn abrasion model. The previous study used a model where bleeding was absent or minimal.

"We are very excited with the results of this latest study, as it opens a new market with a significant unmet medical need and allows Haemacure to leverage its technology, past clinical data and experience in a timely manner", said Joseph Galli, Chairman and CEO of Haemacure.

The use of Haemacure's current fibrin sealant haemostasis formulation for adhesion prevention could significantly accelerate time to market for this indication, by three to five years. This reduced timeframe accelerates Haemacure's ability to address a significant unmet medical need with a potential additional indication for its fibrin sealant. Post-surgical adhesions are estimated to cost the U.S. healthcare system in excess of $2.1 billion annually. The U.S. market for adhesion prevention products in gynaecological surgery is estimated today at $100 million and could grow to US$150-$200 million in fibrin sealant sales.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical haemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first half of calendar 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on the use of fibrin sealant in aesthetics, adhesion prevention, combination with biomaterials, drug delivery, regenerative medecine, skin graft fixation for burn injuries, and wound healing. Haemacure has identified eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure is headquartered in Montreal, Canada and operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.


'/>"/>
SOURCE Haemacure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Invention to prevent surgical adhesions wins Kaye Award
2. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
3. How is H pylori adhesion to gastric cells associated with MUC1 mucin VNTR size?
4. FDA Panel Recommends Approval of SyntheMeds REPEL-CV(R) Adhesion Barrier for Pediatric Patients
5. U.S. Preventive Medicine Announces Nationwide Launch of The Prevention Plan
6. VA Suicide Prevention Panel Completes Draft Report
7. Community-based diabetes prevention program shows promise
8. Indiana Tobacco Prevention and Cessation Awards Grant to Clarian Tobacco Control Center
9. IncentOne Announces Flu Prevention Rewards Program™
10. New HIV Prevention/Anti-Stigma Campaign Featuring HIV Positive & Negative Persons TOGETHER Launches Across the Nation
11. Weight Loss and Disease Prevention Head Home
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... Los Angeles, California (PRWEB) , ... May 26, 2017 , ... ... Canadian senior citizens who visit a doctor for colds or respiratory issues that are ... note that excessive time pressure on doctors may be largely responsible for the problem ...
(Date:5/27/2017)... Rosa, CA (PRWEB) , ... May 27, 2017 , ... ... cause for concern, but a new study from the Osteoarthritis Initiative shows ... to developing knee osteoarthritis. Knowing this in advance may give doctors the opportunity to ...
(Date:5/26/2017)... Fairfax, VA (PRWEB) , ... May 26, 2017 ... ... is pleased to announce a new educational seminar to focus on current legislative ... Regulatory News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will ...
(Date:5/26/2017)... ... 26, 2017 , ... Boar’s Head Brand®, one of the ... Day entertaining that are sure to satisfy your guests’ flavor cravings, while adding ... cheeses featured in these refreshingly balanced recipes are packed with flavor, creating the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... focusing on the Peace Agreements being discussed by President Donald Trump and the rest ... to try to speed up peace talks in the continuous battle between Israel and ...
Breaking Medicine News(10 mins):
(Date:5/8/2017)... May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., ... ("WRB"), a health care service center company based ... WRB specializes in relationship management programs for leading pharmaceutical ... WRB will join Envoy Health ... services for manufacturers, biotech firms, and other service companies. ...
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
(Date:5/4/2017)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... announced that the Company,s first quarter 2017 financial results ... 11, 2017, and that the Company will host a ... that afternoon. Management will provide an overview of the ...
Breaking Medicine Technology: